LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Uždarymo kaina

9.87 2.49

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.83

Max

10.23

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.1M -17M
Darbuotojai	55
EBITDA	4.7M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+44.51% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-09

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	218M 591M
Ankstesnė atidarymo kaina	7.38
Ankstesnė uždarymo kaina	9.87

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.26 / 3.63 Palaikymas ir pasipriešinimas

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-12 23:57; UTC

Karštos akcijos

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

2026-02-12 23:35; UTC

Uždarbis

Pagrindinės rinkos jėgos

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

2026-02-12 23:28; UTC

Uždarbis

Applied Materials Profit Rises on Soaring AI Demand -- Update

2026-02-12 21:47; UTC

Uždarbis

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

2026-02-13 00:00; UTC

Rinkos pokalbiai

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

2026-02-12 23:47; UTC

Rinkos pokalbiai

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

2026-02-12 23:38; UTC

Rinkos pokalbiai

Gold Steady; Could Undergo Technical Recovery -- Market Talk

2026-02-12 23:33; UTC

Uždarbis

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

2026-02-12 23:09; UTC

Rinkos pokalbiai

South32's Hermosa Review Stokes Spending Fears -- Market Talk

2026-02-12 22:55; UTC

Uždarbis

Karštos akcijos

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

2026-02-12 22:46; UTC

Rinkos pokalbiai

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

2026-02-12 22:23; UTC

Uždarbis

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

2026-02-12 22:00; UTC

Uždarbis

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Net $1.52B >AEM

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

2026-02-12 22:00; UTC

Uždarbis

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

2026-02-12 21:57; UTC

Uždarbis

XP 4Q Rev BRL4.95B >XP

2026-02-12 21:52; UTC

Uždarbis

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026-02-12 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-02-12 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-12 21:47; UTC

Uždarbis

Morningstar 4Q Rev $641M >MORN

2026-02-12 21:39; UTC

Uždarbis

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026-02-12 21:38; UTC

Uždarbis

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

44.51% į viršų

12 mėnesių prognozė

Vidutinis 15 USD 44.51%

Aukščiausias 18 USD

Žemiausias 13 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.